COMMUNIQUÉ DE PRESSE

par HBM Healthcare Investments AG (isin : CH0012627250)

HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering

HBM Healthcare Investments AG / Key word(s): IPO
HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering

14.10.2024 / 06:30 CET/CEST


Upstream Bio (Nasdaq: UPB), a previously private company in the HBM Healthcare Investments portfolio, got off to a successful start on the stock market last Friday. The company raised USD 255 million in new capital through the issuance of 15 million shares at a price of USD 17.00 per share. The share price rose to USD 22.00 (+29.4%) on the first day of trading, valuing the company at around USD 1.1 billion.

HBM Healthcare Investments has invested a total of USD 30 million in two financing rounds of Upstream Bio since October 2021. Most recently, the investment was valued at USD 44 million. Following the IPO, HBM Healthcare Investments holds approximately 2.7 million shares with a total value of USD 59.7 million.

Upstream Bio is a biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company is developing verekitug, a unique antibody that targets the receptor for thymic stromal lymphopoietin (TSLP), a key driver of inflammation. Verekitug is currently in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, and the company plans to explore its use in chronic obstructive pulmonary disease (COPD).

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.



End of Media Release


Language:English
Company:HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone:+41438887171
Fax:+41438887172
E-mail:info@hbmhealthcare.com
Internet:https://www.hbmhealthcare.com
ISIN:CH0012627250
Valor:1262725
Listed:SIX Swiss Exchange
EQS News ID:2007323

 
End of NewsEQS News Service

2007323  14.10.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2007323&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6
Voir toutes les actualités de HBM Healthcare Investments AG